Jazz Pharmaceuticals (JAZZ) News Today $138.81 +2.36 (+1.73%) Closing price 03/7/2025 04:00 PM EasternExtended Trading$139.34 +0.53 (+0.39%) As of 09:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $217.00 at HC WainwrightHC Wainwright lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday.March 10 at 8:19 AM | marketbeat.comRuffer LLP Buys New Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Ruffer LLP acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 58,767 shares of the specialty pharmaceutical company's stock, valued at aMarch 10 at 7:54 AM | marketbeat.comVictory Capital Management Inc. Increases Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Victory Capital Management Inc. grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 3.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 262,689 shares of the specialty pharmaceutical comMarch 10 at 3:48 AM | marketbeat.comCM Management LLC Has $1.85 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)CM Management LLC decreased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 25.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,000 shares of the specialty pharmaceutical company's stocMarch 9 at 7:00 AM | marketbeat.comJazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded at UBS GroupMarch 9 at 4:37 AM | americanbankingnews.comTruist Financial Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock PriceMarch 9 at 4:01 AM | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Earns "Overweight" Rating from Morgan StanleyMarch 9 at 2:21 AM | americanbankingnews.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone Sells 7,080 SharesJazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CMO Robert Iannone sold 7,080 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the transaction, the chief marketing officer now owns 82,024 shares of the company's stock, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.March 8 at 9:21 PM | marketbeat.comJazz Pharmaceuticals upgraded to Buy from Neutral at UBSMarch 8 at 3:44 PM | markets.businessinsider.comMorgan Stanley Reaffirms Overweight Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)Morgan Stanley restated an "overweight" rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday.March 8 at 1:06 PM | marketbeat.comJazz Pharmaceuticals (NASDAQ:JAZZ) Upgraded by UBS Group to Buy RatingUBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their price target for the stock from $145.00 to $179.00 in a research report on Friday.March 8 at 8:19 AM | marketbeat.comInsider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Sells 7,080 Shares of StockMarch 8 at 7:08 AM | insidertrades.comUBS Upgrades Jazz Pharmaceuticals (JAZZ)March 8 at 3:16 AM | msn.comTD Cowen Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)March 7 at 5:14 PM | markets.businessinsider.comFirst-in-Class Brain Cancer Drug Strikes a Chord With Jazz Pharma to the Tune of a $935M M&A DealMarch 7 at 5:14 PM | msn.comJazz Pharmaceuticals assumed with an Overweight at Morgan StanleyMarch 7 at 12:12 PM | markets.businessinsider.comJazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $230.00Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a report on Thursday.March 7 at 11:03 AM | marketbeat.comJazz Pharmaceuticals price target raised to $230 from $220 at TruistMarch 7 at 2:10 AM | markets.businessinsider.comJazz Pharmaceuticals (NASDAQ:JAZZ) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday.March 6, 2025 | marketbeat.comTruist Financial Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)March 6, 2025 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Jazz Pharmaceuticals (JAZZ)March 6, 2025 | markets.businessinsider.comJazz Buys Chimerix - A Good Deal To Make With Major Approval Catalyst In PlayMarch 5, 2025 | seekingalpha.comExamining Cashflow Against Jazz Pharmaceuticals' EarningsMarch 5, 2025 | finance.yahoo.comJazz Pharma to acquire Chimerix for ~$935M in cashMarch 5, 2025 | msn.comJazz Pharmaceuticals to acquire Chimerix for $8.55 per share in cashMarch 5, 2025 | markets.businessinsider.comJazz Pharmaceuticals to buy Chimerix for $935 millionMarch 5, 2025 | reuters.comJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology PortfolioMarch 5, 2025 | globenewswire.comJazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology PortfolioMarch 5, 2025 | prnewswire.comZacks.com featured highlights include EverQuote, Jazz Pharmaceuticals, The Progressive, Sony and NatWestMarch 5, 2025 | finance.yahoo.comOppenheimer Asset Management Inc. Increases Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Oppenheimer Asset Management Inc. boosted its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 24.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,588 shares of the speciaMarch 5, 2025 | marketbeat.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Bank of New York Mellon CorpBank of New York Mellon Corp increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 5.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 477,751 shares of the specialtyMarch 5, 2025 | marketbeat.comNeena M. Patil Sells 3,800 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) StockJazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) EVP Neena M. Patil sold 3,800 shares of the business's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares in the company, valued at $4,826,778.66. This trade represents a 10.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.March 4, 2025 | marketbeat.comJazz Pharmaceuticals plc (NASDAQ:JAZZ) CAO Patricia Carr Sells 4,813 SharesJazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CAO Patricia Carr sold 4,813 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the sale, the chief accounting officer now owns 8,237 shares in the company, valued at $1,189,587.54. This represents a 36.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 4, 2025 | marketbeat.comInsider Selling: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells 6,500 Shares of StockJazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CEO Bruce C. Cozadd sold 6,500 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $144.25, for a total value of $937,625.00. Following the completion of the sale, the chief executive officer now directly owns 464,058 shares of the company's stock, valued at approximately $66,940,366.50. This trade represents a 1.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.March 4, 2025 | marketbeat.comNeena M. Patil Sells 3,800 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) StockMarch 4, 2025 | insidertrades.comProficio Capital Partners LLC Purchases Shares of 38,669 Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Proficio Capital Partners LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 38,669 shares of the specialty pharmaceutical company's stock, valueMarch 4, 2025 | marketbeat.comY Intercept Hong Kong Ltd Sells 10,068 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Y Intercept Hong Kong Ltd cut its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 79.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,631 shares of the specialty pharmaceutical company'sMarch 4, 2025 | marketbeat.comJazz Pharmaceuticals plc (JAZZ): Among the Cash-Rich Mid Cap Stocks to Buy NowMarch 3, 2025 | insidermonkey.comPrivate Advisor Group LLC Trims Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)Private Advisor Group LLC lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 36.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,923 shares of the specialty pharmaceutical company's stockMarch 3, 2025 | marketbeat.comJohn G Ullman & Associates Inc. Has $4.90 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)John G Ullman & Associates Inc. cut its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 11.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,750 shareMarch 2, 2025 | marketbeat.comJazz Pharmaceuticals plc Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearMarch 1, 2025 | finance.yahoo.comGW&K Investment Management LLC Grows Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)GW&K Investment Management LLC raised its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 26.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 464,003 shares of the spMarch 1, 2025 | marketbeat.comJazz Pharmaceuticals' (JAZZ) "Overweight" Rating Reiterated at Piper SandlerMarch 1, 2025 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Given New $210.00 Price Target at Needham & Company LLCMarch 1, 2025 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Sees Large Volume Increase After Analyst UpgradeFebruary 28, 2025 | americanbankingnews.comJazz Pharmaceuticals (NASDAQ:JAZZ) Rating Lowered to "Neutral" at Cantor FitzgeraldFebruary 28, 2025 | americanbankingnews.comTruist Financial Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)February 27, 2025 | markets.businessinsider.comJazz Pharmaceuticals price target raised to $200 from $190 at BarclaysFebruary 27, 2025 | markets.businessinsider.comCantor Fitzgerald Downgrades Jazz Pharmaceuticals (JAZZ)February 27, 2025 | msn.comJazz Pharmaceuticals (NASDAQ:JAZZ) Sees Unusually-High Trading Volume on Analyst UpgradeJazz Pharmaceuticals (NASDAQ:JAZZ) Sees Strong Trading Volume Following Analyst UpgradeFebruary 27, 2025 | marketbeat.com Remove Ads Get Jazz Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Media Mentions By Week JAZZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JAZZ News Sentiment▼0.430.53▲Average Medical News Sentiment JAZZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JAZZ Articles This Week▼4410▲JAZZ Articles Average Week Remove Ads Get Jazz Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RPRX News CORT News PRGO News SUPN News PCRX News OMER News NKTR News ASMB News CPIX News LLY News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JAZZ) was last updated on 3/10/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAI Shock Coming on March 18? Prepare NowIf you’re worried about all the recent volatility in the market… Or if you have any money in AI stocks… ...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JAZZ Stock Alerts